Skip to main content

Compare Stocks

Date Range: 

 Odonate TherapeuticsIMARANeuBase TherapeuticsProcessa PharmaceuticalsSynlogic
SymbolNASDAQ:ODTNASDAQ:IMRANASDAQ:NBSENASDAQ:PCSANASDAQ:SYBX
Price Information
Current Price$3.15$8.05$4.95$6.22$3.59
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score1.81.41.51.21.6
Analysis Score3.03.53.50.03.4
Community Score2.12.93.05.02.7
Dividend Score0.00.00.00.00.0
Ownership Score2.50.80.80.80.8
Earnings & Valuation Score1.30.00.00.01.3
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$19.33$35.00$17.33N/A$13.25
% Upside from Price Target513.76% upside334.78% upside250.17% upsideN/A269.08% upside
Trade Information
Market Cap$111.18 million$142.00 million$117.75 million$97.01 million$141.34 million
Beta0.66N/A0.41-0.062.2
Average Volume3,110,170142,264362,73869,541958,896
Sales & Book Value
Annual RevenueN/AN/AN/AN/A$2.22 million
Price / SalesN/AN/AN/AN/A66.06
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.06 per shareN/A$1.35 per share$1.46 per share$4.86 per share
Price / BookN/AN/AN/AN/A0.74
Profitability
Net Income$-111,820,000.00N/A$-17,390,000.00$-3,360,000.00$-51,370,000.00
EPS($4.05)N/A($0.89)N/A($1.70)
Trailing P/E RatioN/A0.00N/A0.00N/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/A-2,761.83%
Return on Equity (ROE)-85.75%N/A-90.43%-79.69%-41.64%
Return on Assets (ROA)-71.45%N/A-77.20%-53.85%-34.39%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.01%N/A
Current Ratio6.68%18.78%10.42%0.14%16.42%
Quick Ratio6.68%18.78%10.42%0.14%16.42%
Ownership Information
Institutional Ownership Percentage96.00%64.53%28.98%N/A39.53%
Insider Ownership Percentage48.90%N/A24.00%54.60%17.95%
Miscellaneous
Employees13727151472
Shares Outstanding38.60 million17.64 million23.18 million15.52 million40.85 million
Next Earnings Date7/29/2021 (Estimated)8/13/2021 (Estimated)8/12/2021 (Estimated)8/4/2021 (Estimated)8/5/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Microbiomes Market to Observe Positive Growth | Players –4D Pharma, Synlogic. – The Manomet Current - The Manomet CurrentMicrobiomes Market to Observe Positive Growth | Players –4D Pharma, Synlogic. – The Manomet Current - The Manomet Current
manometcurrent.com - May 17 at 12:36 PM
Synlogic (NASDAQ:SYBX) Posts Quarterly  Earnings Results, Beats Expectations By $0.03 EPSSynlogic (NASDAQ:SYBX) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS
americanbankingnews.com - May 14 at 3:22 PM
Synlogic, Inc. (NASDAQ:SYBX) Given Consensus Recommendation of "Buy" by BrokeragesSynlogic, Inc. (NASDAQ:SYBX) Given Consensus Recommendation of "Buy" by Brokerages
americanbankingnews.com - May 14 at 2:48 PM
Orbimed Advisors increased stake in Synlogic, Inc. By Investing.com - Investing.comOrbimed Advisors increased stake in Synlogic, Inc. By Investing.com - Investing.com
investing.com - May 14 at 2:45 PM
Phenylketonuria Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Synlogic, Homology Medicines, PTC therapeutics, Rubius Therapeutics, Nestle, BioMarin, SOM Biotech and Others – Clark County Blog - Clark County BlogPhenylketonuria Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Synlogic, Homology Medicines, PTC therapeutics, Rubius Therapeutics, Nestle, BioMarin, SOM Biotech and Others – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 14 at 9:45 AM
Synlogics (SYBX) "Hold" Rating Reiterated at OppenheimerSynlogic's (SYBX) "Hold" Rating Reiterated at Oppenheimer
americanbankingnews.com - May 14 at 6:32 AM
-$0.39 EPS Expected for Synlogic, Inc. (NASDAQ:SYBX) This Quarter-$0.39 EPS Expected for Synlogic, Inc. (NASDAQ:SYBX) This Quarter
americanbankingnews.com - May 13 at 8:12 PM
Human Microbiome Market | Top Leading Countries, Companies, Consumption, Forces Analysis, Revenue, Challenges And Forecast 2025 DuPont, Synlogic Inc., Vedanta Biosciences Inc., Osel Inc., Yakult, Enterome Bioscience, Vithera Pharmaceuticals, Synt - Brockville ObserverHuman Microbiome Market | Top Leading Countries, Companies, Consumption, Forces Analysis, Revenue, Challenges And Forecast 2025 DuPont, Synlogic Inc., Vedanta Biosciences Inc., Osel Inc., Yakult, Enterome Bioscience, Vithera Pharmaceuticals, Synt - Brockville Observer
thebrockvilleobserver.ca - May 13 at 1:51 PM
$SYBX Synlogic Reports Q1 Loss Per Share Of $0.36 - CML News$SYBX Synlogic Reports Q1 Loss Per Share Of $0.36 - CML News
cmlviz.com - May 13 at 8:50 AM
Synlogic Reports First Quarter Financial Results and Provides Business Update - PRNewswireSynlogic Reports First Quarter Financial Results and Provides Business Update - PRNewswire
prnewswire.com - May 13 at 8:50 AM
How Will the Market React to Synlogic Inc (SYBX) Stock Getting a Bullish Rating - InvestorsObserverHow Will the Market React to Synlogic Inc (SYBX) Stock Getting a Bullish Rating - InvestorsObserver
investorsobserver.com - May 12 at 2:48 PM
The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026 - PR Newswire UKThe Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026 - PR Newswire UK
prnewswire.co.uk - May 12 at 9:47 AM
Traders Buy Large Volume of Call Options on Synlogic (NASDAQ:SYBX)Traders Buy Large Volume of Call Options on Synlogic (NASDAQ:SYBX)
americanbankingnews.com - May 11 at 4:40 PM
This is Why a Health Gut is Crucial for Your Wellbeing - StockhouseThis is Why a Health Gut is Crucial for Your Wellbeing - Stockhouse
stockhouse.com - May 11 at 2:12 PM
Atlas Venture Welcomes Samantha Truex as Venture Partner - StreetInsider.comAtlas Venture Welcomes Samantha Truex as Venture Partner - StreetInsider.com
streetinsider.com - May 11 at 9:11 AM
After winding down Quench Bio with a bold dose of honesty, Sam Truex finds perfect fit at Atlas Venture - Endpoints NewsAfter winding down Quench Bio with a bold dose of honesty, Sam Truex finds 'perfect fit' at Atlas Venture - Endpoints News
endpts.com - May 10 at 3:34 PM
Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth - NasdaqCompanies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth - Nasdaq
nasdaq.com - May 10 at 3:34 PM
Atlas Venture Welcomes Samantha Truex as Venture Partner | Business | northwestgeorgianews.com - Rome News-TribuneAtlas Venture Welcomes Samantha Truex as Venture Partner | Business | northwestgeorgianews.com - Rome News-Tribune
northwestgeorgianews.com - May 10 at 8:56 AM
Synlogic (SYBX) Set to Announce Quarterly Earnings on ThursdaySynlogic (SYBX) Set to Announce Quarterly Earnings on Thursday
americanbankingnews.com - May 7 at 10:12 AM
Synlogic (SYBX) Scheduled to Post Earnings on ThursdaySynlogic (SYBX) Scheduled to Post Earnings on Thursday
americanbankingnews.com - May 7 at 9:33 AM
Synlogic Announces First Quarter 2021 Conference Call & Webcast - Yahoo FinanceSynlogic Announces First Quarter 2021 Conference Call & Webcast - Yahoo Finance
finance.yahoo.com - May 6 at 11:50 AM
Synlogic Announces First Quarter 2021 Conference Call & WebcastSynlogic Announces First Quarter 2021 Conference Call & Webcast
finance.yahoo.com - May 6 at 11:50 AM
Microbiome Therapeutics market share to Reach USD 173.8 Million by 2025 - Market PrimesMicrobiome Therapeutics market share to Reach USD 173.8 Million by 2025 - Market Primes
marketprimes.com - May 5 at 1:27 AM
Global Microbiome Therapeutics Market by Type (Upper GIT, Lower GIT, Microbiome Therapeutic), By Application (Inflammatory Bowel Disease (IBD), Orphan Drug, Immuno-oncology, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028 - Good News GumGlobal Microbiome Therapeutics Market by Type (Upper GIT, Lower GIT, Microbiome Therapeutic), By Application (Inflammatory Bowel Disease (IBD), Orphan Drug, Immuno-oncology, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028 - Good News Gum
goodnewsgum.com - May 3 at 6:29 PM
CEO QA Dr Aoife Brennan - Life Science Leader MagazineCEO QA Dr Aoife Brennan - Life Science Leader Magazine
lifescienceleader.com - May 3 at 1:29 PM
DateCompanyBrokerageAction
3/22/2021Odonate TherapeuticsLifesci CapitalDowngrade
3/22/2021Odonate TherapeuticsThe Goldman Sachs GroupLower Price Target
3/22/2021Odonate TherapeuticsJefferies Financial GroupDowngrade
3/22/2021Odonate TherapeuticsCowenDowngrade
9/9/2020Odonate TherapeuticsCi CapitalReiterated Rating
4/26/2021IMARAMorgan StanleyLower Price Target
3/15/2021IMARASVB LeerinkLower Price Target
8/17/2020IMARACitigroupUpgrade
3/18/2021NeuBase TherapeuticsOppenheimerReiterated Rating
2/12/2021NeuBase TherapeuticsHC WainwrightBoost Price Target
12/27/2020NeuBase TherapeuticsRoyal Bank of CanadaReiterated Rating
8/14/2020NeuBase TherapeuticsChardan CapitalReiterated Rating
2/6/2020NeuBase TherapeuticsGuggenheimInitiated Coverage
9/24/2019NeuBase TherapeuticsBTIG ResearchInitiated Coverage
12/8/2020Processa PharmaceuticalsBenchmarkInitiated Coverage
10/28/2020Processa PharmaceuticalsCraig HallumInitiated Coverage
3/24/2021SynlogicJonestradingInitiated Coverage
11/13/2019SynlogicPiper Jaffray CompaniesReiterated Rating
8/9/2019SynlogicWedbushReiterated Rating
(Data available from 5/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.